Latest News and Press Releases

- Activities to support the next stage of clinical development of ACHM B3 candidate are ongoing- - Dosing of pediatric patients in ACHM B3 program and ACHM A3 program is expected to be completed in...

GAINESVILLE, Fla. and CAMBRIDGE, Mass., June 23, 2021 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of...

-AGTC patient advocacy executive director will highlight the state of gene therapy trial recruitment for IRDs- GAINESVILLE, Fla. and CAMBRIDGE, Mass., June 22, 2021 (GLOBE NEWSWIRE) -- Applied...

AGTC Appoints Regulatory Expert, Janet C. Rae, RAC, as SVP of Global Regulatory and Quality GAINESVILLE, Fla. and CAMBRIDGE, Mass., May 26, 2021 (GLOBE NEWSWIRE) -- Applied Genetic Technologies...

- Reported 50% response rate in visual sensitivity among patients in highest dose groups in ongoing Phase 1/2 clinical trial of its XLRP gene therapy candidate for patients who met inclusion criteria...

- Company plans to lease 21,000 square foot build-to-suit cGMP manufacturing facility adjacent to its Florida facility - - Obtained additional $10 million in debt and maturity extension under an...

GAINESVILLE, Fla. and CAMBRIDGE, Mass., May 11, 2021 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of...

-Improved process and validated expression assay support clinical phase product release for the Vista Phase 2/3 XLRP clinical trial- GAINESVILLE, Fla. and CAMBRIDGE, Mass., May 11, 2021 (GLOBE...

-Groups 5 and 6 had a 50% response rate among patients who met the inclusion criteria for the Skyline and Vista trials- -Best Corrected Visual Acuity (BCVA) data continue to provide supportive...

GAINESVILLE, Fla. and CAMBRIDGE, Mass., May 05, 2021 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of...